Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Xentria, Inc.
A Long-term Multicenter Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants are eligible to be included in the study if the following criteria apply:
Completion of XTMAB-16-201 study: completion of Week 12 (Part A) or Week 24 (Part B) assessments.
Participants from XTMAB-16-201 Part A and Part B should be on a stable steroid dose for at least 2 weeks prior to informed consent/Day 1 of XTMAB-16-202 (Day 1 should occur at the next scheduled dosing visit on the assigned dose frequency cohort of XTMAB 16 201 ± 2 weeks).
You may not be if
Participants are excluded from the study if any of the following criteria apply:
Evidence of treatment-related AEs requiring treatment discontinuation per XTMAB-16-201 protocol observed in XTMAB-16-201 study.
Evidence of treatment failure observed in XTMAB-16-201 study per protocol definition.
Pregnant or breastfeeding women or women who are planning to be pregnant during the course of the study.
Clareo Health | An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
